Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-cholesterol greater than or equal to 100 mg/dL at screening~* Men and nonpregnant, nonlactating women~* Use of stable lipid-modifying therapy for at least 4 weeks prior to screening that includes ezetimibe 10mg daily~Exclusion Criteria:~* Fasting blood triglycerides greater than or equal to 500 mg/dL~* Body Mass Index (BMI) greater than or equal to 50 kg/m2~* Recent history of clinically significant cardiovascular disease~* Use of statin therapy where doses are greater than those defined as low-dose within 4 weeks prior to screening; where low-dose is defined as an average daily dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bempedoic acid (Type: EXPERIMENTAL): bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
- placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)

Based on this trial design, predict the completion outcome and termination type (if applicable).